opb-111077
Small moleculeexperimental
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2012 (NCT01711034)
Timeline
Indications
Mechanism of action
STAT3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- opb-111077
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04049825 | Phase 1 | Aug 31, 2019 | Otsuka |
| NCT03197714 | Phase 1 | Jun 1, 2017 | Apices Soluciones S.L., Otsuka, Universidad Complutense de Madrid |
| NCT03158324 | Phase 2 | May 22, 2017 | National University of Singapore, Otsuka |
| NCT03063944 | Phase 1 | Mar 17, 2017 | Otsuka, Thomas Jefferson University |
| NCT02250170 | Phase 1 | Oct 23, 2014 | Otsuka, Seoul National University, University of Ulsan |
| NCT01942083 | Phase 1 | May 29, 2013 | Otsuka |
| NCT01711034 | Phase 1 | Jun 1, 2012 | Otsuka |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 7 | 4 | 2 | 2012 |
| Apices Soluciones S.L. | For profit | 1 | 0 | 1 | 2017 |
| National University of Singapore | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Thomas Jefferson University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Universidad Complutense de Madrid | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Ulsan | Academic/Hospital | 1 | 0 | 1 | 2014 |
7 organizations
Page 1 / 1